These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35439627)

  • 1. Design, synthesis and biological evaluation of (R)-5-methylpyrrolidin-2-ones as p300 bromodomain inhibitors with Anti-Tumor activities in multiple tumor lines.
    Liu R; Yang H; Chen Z; Zhou K; Shi Q; Li J; Huang Y; Huang X; Li Y
    Bioorg Chem; 2022 Jul; 124():105803. PubMed ID: 35439627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
    Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
    Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current development of CBP/p300 inhibitors in the last decade.
    He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
    Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel benzimidazole derivatives as potent p300 bromodomain inhibitors with anti-proliferative activity in multiple cancer cells.
    Chen Z; Li J; Yang H; He Y; Shi Q; Chang Q; Liu R; Huang X; Li Y
    Bioorg Med Chem; 2022 Jul; 66():116784. PubMed ID: 35569250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights revealed by the cocrystal structure of CCS1477 in complex with CBP bromodomain.
    Xu H; Luo G; Wu T; Hu J; Wang C; Wu X; Zhang Y; Xu Y; Xiang Q
    Biochem Biophys Res Commun; 2022 Oct; 623():17-22. PubMed ID: 35868068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
    Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP
    Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
    Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
    Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of tetrahydroquinolin derivatives as potent inhibitors of CBP bromodomain.
    Chen Y; Bi X; Zhang F; Sun Z; Xu P; Jiang H; Lu W; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Chem; 2020 Aug; 101():103991. PubMed ID: 32559581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
    Chang Q; Li J; Deng Y; Zhou R; Wang B; Wang Y; Zhang M; Huang X; Li Y
    J Med Chem; 2024 Feb; 67(4):2466-2486. PubMed ID: 38316017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
    Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
    Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins.
    Thomas JE; Wang M; Jiang W; Wang M; Wang L; Wen B; Sun D; Wang S
    J Med Chem; 2023 Jun; 66(12):8178-8199. PubMed ID: 37276143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
    Xiang Q; Wu T; Zhang C; Wang C; Xu H; Hu Q; Hu J; Luo G; Zhuang X; Wu X; Zhang Y; Xu Y
    Bioorg Chem; 2024 Jan; 142():106950. PubMed ID: 37924753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors.
    Xiong Y; Zhang M; Li Y
    Curr Med Chem; 2020; 27(33):5583-5598. PubMed ID: 31364510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain.
    Huang L; Li H; Li L; Niu L; Seupel R; Wu C; Cheng W; Chen C; Ding B; Brennan PE; Yang S
    J Med Chem; 2019 May; 62(9):4526-4542. PubMed ID: 30998845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.
    Lai KW; Romero FA; Tsui V; Beresini MH; de Leon Boenig G; Bronner SM; Chen K; Chen Z; Choo EF; Crawford TD; Cyr P; Kaufman S; Li Y; Liao J; Liu W; Ly J; Murray J; Shen W; Wai J; Wang F; Zhu C; Zhu X; Magnuson S
    Bioorg Med Chem Lett; 2018 Jan; 28(1):15-23. PubMed ID: 29169673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay of bromodomain and histone acetylation in the regulation of p300-dependent genes.
    Chen J; Ghazawi FM; Li Q
    Epigenetics; 2010 Aug; 5(6):509-15. PubMed ID: 20505343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of CZL-046 with an (
    Chen Z; Yang H; Zhang Y; Lyu X; Shi Q; Zhang C; Wang X; Wang Z; Zhang Y; Deng Y; Wang Y; Huang Y; Xu Y; Huang X; Li Y
    J Med Chem; 2024 Oct; 67(20):18606-18628. PubMed ID: 39356741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
    Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
    J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based drug optimization and biological evaluation of tetrahydroquinolin derivatives as selective and potent CBP bromodomain inhibitors.
    Bi X; Chen Y; Sun Z; Lu W; Xu P; Lu T; Ding H; Zhang N; Jiang H; Chen K; Zhou B; Luo C
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127480. PubMed ID: 32882416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.